On June 17, 2022, the Advanced Cardiac Valve Center of the University of Virginia successfully completed the first implantation of the VenusP-Valve (an innovative device independently developed by China for transcatheter pulmonary valve implantation) in the United States, under the proctorship of the Heart Valve Team of our Cardiology Department.
The official visit to the United States by Professor Feng Yuan, Senior Interventional Cardiologist of the Department of Cardiology, received full support and expedited approval from the hospital administration. This is the first time that a Chinese expert in transcatheter valve intervention has been invited to proctor interventional procedures of the heart valve in the United States, and it has also created a precedent for the clinical use of transcatheter valve in the United States which is independently developed by China. The event represents a milestone achievement in the history of interventional cardiology in China.
On May 23, 2022, the U.S. FDA approved the Advanced Heart Valve Center of the University of Virginia for two emergency humanitarian cases of transcatheter pulmonary valve implantation using the VenusP-Valve. Due to the extensive experience of our hospital in the field of transcatheter pulmonary valve implantation and the clinical application of the VenusP-Valve, we received an invitation from the Advanced Heart Valve Center of the University of Virginia on May 25, 2022 to assign a specialist to the United States to proctor the procedure. Considering the significance of this visit, our hospital administration immediately launched a rapid approval process to specifically approve Professor Feng Yuan of the Department of Cardiology to visit the United States.
The Heart Valve Team of the Department of Cardiology, led by Professor Chen Mao and Professor Feng Yuan, conducted several in-depth pre-procedural discussions with the Advanced Heart Valve Center of the University of Virginia, and formulated a detailed strategic plan based on the patient's clinical status and pulmonary anatomy. On June 17, the procedure was performed in the hybrid operating room of the Advanced Heart Valve Center of the University of Virginia, after completing the in vitro simulator-based hands-on training, both under the proctorship of Professor Feng Yuan.
The patient, a 21-year-old male with severe pulmonary regurgitation, significant right ventricular and pulmonary artery dilation, and left ventricular dysfunction, had previously undergone surgical transvalvular patch repair for Tetralogy of Fallot. The index procedure was performed with patient awake and under local anesthesia, the right femoral vein was punctured to be used as the main access for valve deliver. With intraprocedural angiography and balloon sizing results available, the China and U.S. teams discussed again online, and agreed to proceed with a P34-25 VenusP-Valve (waist diameter = 34mm, waist length = 25mm). The implantation process was very smooth, immediate comprehensive assessment with angiography and echocardiography showed that the prothesis position was satisfactory, with no paravalvular leak or residual pressure difference, and bilateral pulmonary artery flow was not affected.
After the procedure, Professor Feng Yuan reviewed the procedural details and exchanged the experience of transcatheter pulmonary valve implantation and VenusP-Valve with Professor Scott Lim, director of the Advanced Heart Valve Center of the University of Virginia. Echocardiography performed on the next day showed that there was no pulmonary regurgitation, the right ventricular diameter reduced significantly, and the left ventricular function normalized. The patient’s recovery was rapid and uneventful, and was discharged on June 18 (within 24 hours after the procedure).
As one of the largest heat valve centers in China, the Heat Valve Team of the Department of Cardiology are experienced in the interventional treatment of aortic, pulmonary, mitral and tricuspid valve diseases. The team has performed more than 2,000 cases of transcatheter valve intervention, and pioneered the first clinical use of a variety of innovative transcatheter valve devices or procedures in the world, in Asia or in China. As a leading heart valve center in China, the team has also proctored transcatheter valve procedures in Argentina, India, the Philippines, China Hong Kong and other countries or regions.
From http://www.wchscu.cn/details/65516.html
